Home > Publications Database > Progression of biological markers in spinocerebellar ataxia type 3: longitudinal analysis of prospective data from the ESMI cohort. > print

001     280023
005     20250824001715.0
024 7 _ |a 10.1016/j.lanepe.2025.101339
|2 doi
024 7 _ |a pmid:40678042
|2 pmid
024 7 _ |a pmc:PMC12270660
|2 pmc
024 7 _ |a altmetric:178874846
|2 altmetric
037 _ _ |a DZNE-2025-00867
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Berger, Moritz
|b 0
245 _ _ |a Progression of biological markers in spinocerebellar ataxia type 3: longitudinal analysis of prospective data from the ESMI cohort.
260 _ _ |a [Amsterdam]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1755681458_25773
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominantly inherited adult-onset disease. We aimed to describe longitudinal changes in clinical and biological findings and to identify predictors for clinical progression.We used data from participants enrolled in the ESMI cohort collected between Nov 09, 2016 and July 18, 2023. The data freeze included data from 14 sites in five European countries and the United States. We assessed ataxia with the Scale for the Assessment and Rating of Ataxia (SARA). We measured disease-specific mutant ataxin-3 protein (ATXN3) and neurofilament light chain (NfL) in plasma and performed MRIs. Data were analysed by regression modelling on a timescale defined by onset. The onset of abnormality of a marker was defined as the time at which its value, as determined by modelling, exceeded the mean ± 2 SD of healthy controls. To study responsiveness of markers, we determined the sensitivity to change ratios (SCSs).Data from 291 SCA3 mutation carriers before and after clinical onset and 121 healthy controls were included. NfL levels became abnormal in SCA3 mutation carriers more than 20 years (-21.5 years [95% CI n.d.-9.5]) before onset. The earliest MRI abnormality was volume loss of medulla oblongata (-4.7 years [95% CI n.d.-3.3]). The responsiveness of markers depended on the disease stage. Across all stages, pons volume had the highest responsiveness with an SCS of 1.35 [95% CI 1.11-1.78] exceeding that of SARA (0.99 [95% CI 0.88-1.11]). In SCA3, lower age (p = 0.0459 [95% CI of slope change -0.0018 to 0.0000]) and lower medulla oblongata volume (p < 0.0001 [95% CI of slope change -0.0298 to -0.0115]) were predictors of SARA progression.Our study provides quantitative information on the progression of biological markers in SCA3 mutation carriers before and after onset of ataxia, and allowed the identification of predictors for clinical progression. Our data could prove useful for the design of future clinical trials.HEU Joint Programme - Neurodegenerative Disease Research (JPND) (Federal Ministry of Education and Research, Germany; The Netherlands Organisation for Health Research and Development; Foundation for Science and Technology, Portugal; Medical Research Council, Regional Fund for Science and Technology, Azores), and Servier. At the US sites this work was in part supported by the National Ataxia Foundation and the National Institute of Neurological Disorders and Stroke (NINDS) grant R01NS080816.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ATXN3
|2 Other
650 _ 7 |a Biomarker
|2 Other
650 _ 7 |a Disease modelling
|2 Other
650 _ 7 |a MRI
|2 Other
650 _ 7 |a NfL
|2 Other
650 _ 7 |a Spinocerebellar ataxia
|2 Other
650 _ 7 |a Staging model
|2 Other
700 1 _ |a Garcia-Moreno, Hector
|b 1
700 1 _ |a Ferreira, Mónica
|0 P:(DE-2719)9003289
|b 2
|u dzne
700 1 _ |a Hubener-Schmid, Jeannette
|b 3
700 1 _ |a Schaprian, Tamara
|0 P:(DE-2719)2812594
|b 4
|u dzne
700 1 _ |a Wegner, Philipp
|0 P:(DE-2719)9002349
|b 5
|u dzne
700 1 _ |a Elter, Tim-Lukas
|0 P:(DE-2719)9001258
|b 6
|u dzne
700 1 _ |a Teichmann, Kennet M
|0 P:(DE-2719)9002253
|b 7
|u dzne
700 1 _ |a Santana, Magda M
|b 8
700 1 _ |a Grobe-Einsler, Marcus
|0 P:(DE-2719)9001510
|b 9
|u dzne
700 1 _ |a Oender, Demet
|0 P:(DE-2719)9000685
|b 10
|u dzne
700 1 _ |a Koyak, Berkan S C
|0 P:(DE-2719)9001550
|b 11
|u dzne
700 1 _ |a Bernsen, Sarah
|0 P:(DE-2719)9000485
|b 12
|u dzne
700 1 _ |a Pereira de Almeida, Luís
|b 13
700 1 _ |a Silva, Patrick
|b 14
700 1 _ |a Ribeiro, Joana Afonso
|b 15
700 1 _ |a Cunha, Inês
|b 16
700 1 _ |a Gonzalez-Robles, Cristina
|b 17
700 1 _ |a Khan, Shamsher
|b 18
700 1 _ |a Heslegrave, Amanda
|b 19
700 1 _ |a Zetterberg, Henrik
|b 20
700 1 _ |a Lima, Manuela
|b 21
700 1 _ |a Raposo, Mafalda
|b 22
700 1 _ |a Ferreira, Ana F
|b 23
700 1 _ |a Vasconcelos, João
|b 24
700 1 _ |a van de Warrenburg, Bart P
|b 25
700 1 _ |a van Gaalen, Judith
|b 26
700 1 _ |a van Prooije, Teije H
|b 27
700 1 _ |a de Vries, Jeroen
|b 28
700 1 _ |a Schols, Ludger
|0 P:(DE-2719)2810795
|b 29
|u dzne
700 1 _ |a Riess, Olaf
|b 30
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 31
|u dzne
700 1 _ |a Timmann, Dagmar
|b 32
700 1 _ |a Thieme, Andreas
|b 33
700 1 _ |a Erdlenbruch, Friedrich
|b 34
700 1 _ |a Infante, Jon
|b 35
700 1 _ |a Pelayo-Negro, Ana L
|b 36
700 1 _ |a Manrique, Leire
|b 37
700 1 _ |a Reetz, Kathrin
|b 38
700 1 _ |a Dogan, Imis
|b 39
700 1 _ |a Oz, Gulin
|b 40
700 1 _ |a Joers, James M
|b 41
700 1 _ |a Bushara, Khalafalla
|b 42
700 1 _ |a Onyike, Chiadikaobi
|b 43
700 1 _ |a Povazan, Michal
|b 44
700 1 _ |a Jacobi, Heike
|b 45
700 1 _ |a Schmahmann, Jeremy D
|b 46
700 1 _ |a Ratai, Eva-Maria
|b 47
700 1 _ |a Schmid, Matthias
|0 P:(DE-2719)2811245
|b 48
|u dzne
700 1 _ |a Giunti, Paola
|b 49
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 50
|u dzne
700 1 _ |a Faber, Jennifer
|0 P:(DE-2719)2811327
|b 51
|e Last author
|u dzne
773 _ _ |a 10.1016/j.lanepe.2025.101339
|g Vol. 55, p. 101339 -
|0 PERI:(DE-600)3055963-7
|p 101339
|t The lancet / Regional health. Europe
|v 55
|y 2025
|x 2666-7762
856 4 _ |u https://pub.dzne.de/record/280023/files/DZNE-2025-00867%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/280023/files/DZNE-2025-00867.pdf
856 4 _ |u https://pub.dzne.de/record/280023/files/DZNE-2025-00867%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/280023/files/DZNE-2025-00867%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/280023/files/DZNE-2025-00867%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/280023/files/DZNE-2025-00867.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:280023
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9003289
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812594
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9002349
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 6
|6 P:(DE-2719)9001258
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9002253
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9001510
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9000685
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9001550
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9000485
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2810795
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)2811275
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 48
|6 P:(DE-2719)2811245
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 50
|6 P:(DE-2719)2810314
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 51
|6 P:(DE-2719)2811327
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-20
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a IF >= 20
|0 StatID:(DE-HGF)9920
|2 StatID
|b LANCET REG HEALTH-EU : 2022
|d 2024-12-20
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET REG HEALTH-EU : 2022
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1180
|2 StatID
|b Current Contents - Social and Behavioral Sciences
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T14:52:56Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T14:52:56Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T14:52:56Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0130
|2 StatID
|b Social Sciences Citation Index
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 0
920 1 _ |0 I:(DE-2719)1011103
|k AG Spottke
|l Clinical Research Platform (CRP)
|x 1
920 1 _ |0 I:(DE-2719)1011401
|k Clinical Research Platform (CRP)
|l Clinical Research Platform (CRP)
|x 2
920 1 _ |0 I:(DE-2719)5000005
|k AG Schöls
|l Clinical Neurogenetics
|x 3
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 4
920 1 _ |0 I:(DE-2719)5000075
|k AG Radbruch
|l Clinical Neuroimaging
|x 5
920 1 _ |0 I:(DE-2719)1013028
|k AG Schmid Bonn
|l Mathematics, statistics and informatics methods for support of population studies and clinical research
|x 6
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 7
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1011103
980 _ _ |a I:(DE-2719)1011401
980 _ _ |a I:(DE-2719)5000005
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)5000075
980 _ _ |a I:(DE-2719)1013028
980 _ _ |a I:(DE-2719)1011101
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21